Mind Medicine (MindMed) (NASDAQ:MNMD) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) to a strong-buy rating in a research note released on Friday, Zacks.com reports. A number of other equities research analysts also recently commented on the company. Roth Capital raised Mind Medicine (MindMed) to a strong-buy rating in a report on Wednesday, July 24th. […]
DA Davidson Reaffirms Neutral Rating for Procter & Gamble (NYSE:PG)
Procter & Gamble (NYSE:PG – Get Free Report)‘s stock had its “neutral” rating reiterated by investment analysts at DA Davidson in a research note issued on Tuesday, Benzinga reports. They currently have a $159.00 target price on the stock. DA Davidson’s price objective would suggest a potential downside of 8.61% from the company’s current price. […]
DA Davidson Increases ACI Worldwide (NASDAQ:ACIW) Price Target to $57.00
ACI Worldwide (NASDAQ:ACIW – Get Free Report) had its target price raised by equities research analysts at DA Davidson from $52.00 to $57.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the technology company’s stock. DA Davidson’s target price would indicate a […]
Mind Medicine (MindMed) (NASDAQ:MNMD) Raised to “Strong-Buy” at Leerink Partnrs
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) was upgraded by investment analysts at Leerink Partnrs to a “strong-buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. Other equities research analysts have also issued research reports about the company. Canaccord Genuity Group lowered their target price on Mind Medicine […]
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com
StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a research report released on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright reissued a buy rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research note on Friday, […]
Tenet Healthcare (NYSE:THC) Receives New Coverage from Analysts at KeyCorp
KeyCorp began coverage on shares of Tenet Healthcare (NYSE:THC – Free Report) in a research note released on Friday morning, Marketbeat reports. The firm issued an overweight rating and a $200.00 price objective on the stock. KeyCorp also issued estimates for Tenet Healthcare’s FY2024 earnings at $10.67 EPS, FY2025 earnings at $11.54 EPS and FY2026 […]
Universal Health Services (NYSE:UHS) Coverage Initiated at KeyCorp
KeyCorp started coverage on shares of Universal Health Services (NYSE:UHS – Free Report) in a research report released on Friday, MarketBeat Ratings reports. The brokerage issued a sector weight rating on the health services provider’s stock. KeyCorp also issued estimates for Universal Health Services’ FY2024 earnings at $15.60 EPS, FY2025 earnings at $17.36 EPS and […]
Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $124.64
Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have earned an average recommendation of “Buy” from the fourteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Fourteen equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage […]
Biogen (NASDAQ:BIIB) Stock Rating Reaffirmed by Raymond James
Raymond James reissued their market perform rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research note released on Thursday, MarketBeat reports. A number of other equities research analysts also recently commented on BIIB. Needham & Company LLC restated a buy rating and issued a $285.00 price objective on shares of Biogen in […]
Raymond James Reiterates “Outperform” Rating for Immunovant (NASDAQ:IMVT)
Raymond James reissued their outperform rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research note issued to investors on Thursday, MarketBeat reports. Raymond James currently has a $36.00 target price on the stock. Several other research firms also recently weighed in on IMVT. JPMorgan Chase & Co. decreased their price objective on […]
argenx (NASDAQ:ARGX) Receives Strong-Buy Rating from Raymond James
Raymond James restated their strong-buy rating on shares of argenx (NASDAQ:ARGX – Free Report) in a research note released on Thursday, MarketBeat.com reports. The firm currently has a $605.00 price target on the stock. Other analysts also recently issued research reports about the company. Guggenheim restated a buy rating and issued a $585.00 price target […]
last updated on 15 Oct 16:12